# Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

> **NCT01459887** · PHASE3 · COMPLETED · sponsor: **Shanghai CP Guojian Pharmaceutical Co., Ltd.** · enrollment: 278 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** CHOP combined with CMAB304
- **DRUG:** CHOP, CMAB304

## Key facts

- **NCT ID:** NCT01459887
- **Lead sponsor:** Shanghai CP Guojian Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2010-12
- **Final completion:** 2011-02
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2011-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459887, "Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01459887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*